{
  "schema_version": "2.0",
  "description": "天星医疗的双语结构化披露数据，覆盖 2023–2025 经审核往绩、2026 年中期业绩、产品与医院覆盖、海外业务、研发、现金流、管理层及正式披露风险。",
  "description_en": "Bilingual structured disclosure data for Star Sports Medicine, covering its audited FY2023–FY2025 track record, 2026 interim results, products and hospital coverage, overseas business, R&D, cash flow, management and formally disclosed risks.",
  "scope": "HKEX 招股章程、2025 年利润分配决议、2026 年中期业绩及截至 2026-08-18 的股份回购计划公告；年度历史数据来自招股章程经审核往绩，中期数据来自正式发布的未经审核中期业绩。",
  "methodology_url": "https://pureir.top/#method",
  "usage_notice": "PureIR 为独立、非官方信息平台。本数据帮助读者阅读正式披露，不构成投资建议，也不替代原始文件。",
  "usage_notice_en": "PureIR is an independent, unofficial information platform. This dataset supports reading of formal disclosure; it is not investment advice and does not replace the original filings.",
  "publisher": {
    "name": "PureIR",
    "url": "https://pureir.top/"
  },
  "data_as_of": "2026-06-30",
  "last_reviewed": "2026-08-30",
  "company": {
    "name": "Beijing Star Sports Medicine Co., Ltd.",
    "name_zh": "北京天星医疗股份有限公司",
    "stock_code": "01609",
    "exchange": "HKEX",
    "official_website": "https://starsportmed.com/",
    "investor_relations_contact_url": "https://starsportmed.com/case/category/announcements-and-circulars",
    "description": "天星医疗是运动医学医疗器械公司，以生物材料、影像动力、智慧医疗及再生医学组织工程四个技术平台提供植入物、手术设备及相关耗材。2026 年上半年收入为人民币 163.427 百万元，毛利率 74.2%，期内利润为人民币 27.402 百万元，经调整期内利润为人民币 48.897 百万元；产品进入全国超过 3,000 家医院。",
    "description_en": "Star Sports Medicine is a sports-medicine medical-device company whose biomaterials, imaging and power, smart healthcare and regenerative-medicine tissue-engineering platforms support implants, surgical equipment and related consumables. In the first half of 2026, revenue was RMB163.427 million, gross margin was 74.2%, profit for the period was RMB27.402 million and adjusted profit was RMB48.897 million; its products had entered more than 3,000 hospitals in China.",
    "summary_sources": [
      {
        "label": "2026 年中期财务摘要",
        "label_en": "2026 interim financial highlights",
        "source_type": "hkex_filing",
        "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
        "pdf_page": 1
      },
      {
        "label": "医院覆盖与海外业务",
        "label_en": "Hospital coverage and overseas business",
        "source_type": "hkex_filing",
        "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
        "pdf_page": 10
      },
      {
        "label": "2023–2025 经审核往绩",
        "label_en": "Audited FY2023–FY2025 track record",
        "source_type": "hkex_filing",
        "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
        "pdf_page": 17
      }
    ]
  },
  "latest_update": {
    "title_zh": "2026 年中期业绩",
    "title_en": "2026 interim results",
    "status_zh": "正式中期业绩 · 未经审核",
    "status_en": "Formal interim results · unaudited",
    "published_zh": "公告发布于 2026 年 8 月 17 日",
    "published_en": "Announcement published 17 August 2026",
    "caveat_zh": "以下数字来自公司正式中期业绩公告，期间为截至 2026 年 6 月 30 日止六个月，未经审核；年度历史图表使用招股章程内经审核的 2023–2025 往绩，中期数字单独列示。",
    "caveat_en": "The figures below are from the formal interim-results announcement for the six months ended 30 June 2026 and are unaudited. Historical annual charts use the audited FY2023–FY2025 track record in the prospectus, with interim figures shown separately."
  },
  "latest_updates": [
    {
      "metric_id": "h1_revenue",
      "label": "中期收入",
      "label_en": "Interim revenue",
      "display": "RMB 163.4m",
      "display_en": "RMB163.4m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 163.427,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比增长 21.6%；毛利同比增长 21.8% 至人民币 121.296 百万元。",
      "detail_en": "Up 21.6%; gross profit increased 21.8% to RMB121.296 million.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_reported_profit",
      "label": "中期期内利润",
      "label_en": "Interim reported profit",
      "display": "RMB 27.4m",
      "display_en": "RMB27.4m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 27.402,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比下降 26.1%；公司列报的非国际财务报告准则经调整期内利润为人民币 48.897 百万元，同比增长 24.3%。",
      "detail_en": "Down 26.1%; company-reported non-IFRS adjusted profit for the period was RMB48.897 million, up 24.3%.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_overseas_revenue",
      "label": "海外收入",
      "label_en": "Overseas revenue",
      "display": "RMB 40.7m",
      "display_en": "RMB40.7m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 40.698,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比增长 70.6%，占收入 24.9%；公司披露已在超过 60 个国家和地区取得超过 200 项监管批准及注册。",
      "detail_en": "Up 70.6% and representing 24.9% of revenue; the company disclosed more than 200 regulatory approvals and registrations across over 60 countries and regions.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 10
    }
  ],
  "highlights": [
    {
      "metric_id": "h1_revenue",
      "label": "中期收入",
      "label_en": "Interim revenue",
      "display": "RMB 163.4m",
      "display_en": "RMB163.4m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 163.427,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比增长 21.6%；毛利同比增长 21.8% 至人民币 121.296 百万元。",
      "detail_en": "Up 21.6%; gross profit increased 21.8% to RMB121.296 million.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_adjusted_profit",
      "label": "经调整期内利润",
      "label_en": "Adjusted profit for the period",
      "display": "RMB 48.9m",
      "display_en": "RMB48.9m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 48.897,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元（非国际财务报告准则）",
      "unit_display_en": "RMB million (non-IFRS)",
      "detail": "同比增长 24.3%；同期列报期内利润为人民币 27.402 百万元，差异主要包括上市费用。",
      "detail_en": "Up 24.3%; reported profit for the period was RMB27.402 million, with the difference primarily including listing expenses.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_overseas_revenue",
      "label": "海外收入",
      "label_en": "Overseas revenue",
      "display": "RMB 40.7m",
      "display_en": "RMB40.7m",
      "period": "2026H1",
      "period_zh": "截至 2026 年 6 月 30 日止六个月",
      "period_en": "Six months ended 30 June 2026",
      "value": 40.698,
      "currency": "RMB",
      "unit": "million",
      "unit_display_zh": "人民币百万元",
      "unit_display_en": "RMB million",
      "detail": "同比增长 70.6%，占收入 24.9%；公司在超过 60 个国家和地区取得超过 200 项监管批准及注册证书。",
      "detail_en": "Up 70.6% and representing 24.9% of revenue; the company held more than 200 regulatory approvals and registrations across over 60 countries and regions.",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 10
    }
  ],
  "narrative": [
    {
      "title": "四个技术平台连接产品组合",
      "title_en": "Four technology platforms connect the product portfolio",
      "text": "公司以生物材料、影像动力、智慧医疗及再生医学组织工程平台，形成植入物、有源手术设备、运动医学手术机器人、AI 运动处方及再生医学器械等产品基础。",
      "text_en": "The biomaterials, imaging and power, smart healthcare and regenerative-medicine tissue-engineering platforms underpin implants, active surgical devices, sports-medicine surgical robots, AI exercise prescriptions and regenerative-medicine devices.",
      "period": "2026H1",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 11
    },
    {
      "title": "医院覆盖支撑国内商业化",
      "title_en": "Hospital coverage supports domestic commercialisation",
      "text": "截至 2026 年 6 月 30 日，公司产品已进入全国超过 3,000 家医院，其中三级医院超过 1,000 家。该披露反映其经销网络与临床覆盖规模，不等同于医院采购量或终端使用量。",
      "text_en": "At 30 June 2026, the company's products had entered more than 3,000 hospitals in China, including over 1,000 tertiary hospitals. This indicates distribution and clinical coverage, not hospital purchasing volume or end-use volume.",
      "period": "2026-06-30",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 10
    },
    {
      "title": "海外增长与注册并行",
      "title_en": "Overseas growth and registrations advance together",
      "text": "2026 年上半年海外收入同比增长 70.6%，收入占比升至 24.9%；同期公司披露在超过 60 个国家和地区取得超过 200 项监管批准及注册证书。",
      "text_en": "Overseas revenue grew 70.6% in the first half of 2026 and its revenue share rose to 24.9%; the company also disclosed more than 200 regulatory approvals and registrations across over 60 countries and regions.",
      "period": "2026H1",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 10
    },
    {
      "title": "列报利润与经调整利润需并读",
      "title_en": "Reported and adjusted profit should be read together",
      "text": "2026 年上半年期内利润为人民币 27.402 百万元，同比下降 26.1%；剔除上市费用等调整后，公司列报的非国际财务报告准则利润为人民币 48.897 百万元，同比增长 24.3%。",
      "text_en": "Profit for the first half of 2026 was RMB27.402 million, down 26.1%. After adjustments including listing expenses, company-reported non-IFRS profit was RMB48.897 million, up 24.3%.",
      "period": "2026H1",
      "value_type": "editorial_synthesis",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 17
    }
  ],
  "financials": [
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2023",
      "value": 238.542,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2023",
      "value": 177.308,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "net_profit",
      "label": "净利润",
      "label_en": "Net profit",
      "period": "FY2023",
      "value": 57.112,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2024",
      "value": 327.119,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2024",
      "value": 227.595,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "net_profit",
      "label": "净利润",
      "label_en": "Net profit",
      "period": "FY2024",
      "value": 95.389,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "revenue",
      "label": "收入",
      "label_en": "Revenue",
      "period": "FY2025",
      "value": 402.751,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "gross_profit",
      "label": "毛利",
      "label_en": "Gross profit",
      "period": "FY2025",
      "value": 298.619,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "net_profit",
      "label": "净利润",
      "label_en": "Net profit",
      "period": "FY2025",
      "value": 136.97,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 17
    },
    {
      "metric_id": "h1_revenue",
      "label": "中期收入",
      "label_en": "Interim revenue",
      "period": "2026H1",
      "value": 163.427,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_gross_profit",
      "label": "中期毛利",
      "label_en": "Interim gross profit",
      "period": "2026H1",
      "value": 121.296,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_profit",
      "label": "中期期内利润",
      "label_en": "Interim profit for the period",
      "period": "2026H1",
      "value": 27.402,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 1
    },
    {
      "metric_id": "h1_gross_margin",
      "label": "中期毛利率",
      "label_en": "Interim gross margin",
      "period": "2026H1",
      "value": 74.2,
      "currency": "N/A",
      "unit": "percent",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 15
    }
  ],
  "business_revenue": [
    {
      "metric_id": "implant_revenue",
      "label": "植入物收入",
      "label_en": "Implants revenue",
      "period": "FY2023",
      "value": 186.516,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 11
    },
    {
      "metric_id": "equipment_consumables_revenue",
      "label": "手术设备及相关耗材收入",
      "label_en": "Surgical equipment and related consumables revenue",
      "period": "FY2023",
      "value": 51.919,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 11
    },
    {
      "metric_id": "implant_revenue",
      "label": "植入物收入",
      "label_en": "Implants revenue",
      "period": "FY2024",
      "value": 249.987,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 11
    },
    {
      "metric_id": "equipment_consumables_revenue",
      "label": "手术设备及相关耗材收入",
      "label_en": "Surgical equipment and related consumables revenue",
      "period": "FY2024",
      "value": 76.986,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 11
    },
    {
      "metric_id": "implant_revenue",
      "label": "植入物收入",
      "label_en": "Implants revenue",
      "period": "FY2025",
      "value": 310.375,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 11
    },
    {
      "metric_id": "equipment_consumables_revenue",
      "label": "手术设备及相关耗材收入",
      "label_en": "Surgical equipment and related consumables revenue",
      "period": "FY2025",
      "value": 92.02,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 11
    },
    {
      "metric_id": "implant_revenue",
      "label": "植入物收入",
      "label_en": "Implants revenue",
      "period": "2026H1",
      "value": 125.436,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 7
    },
    {
      "metric_id": "equipment_consumables_revenue",
      "label": "手术设备及相关耗材收入",
      "label_en": "Surgical equipment and related consumables revenue",
      "period": "2026H1",
      "value": 37.815,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 7
    }
  ],
  "operating_metrics": [
    {
      "metric_id": "covered_hospitals_floor",
      "label": "产品进入医院",
      "label_en": "Hospitals reached by products",
      "period": "2026-06-30",
      "value": 3000,
      "currency": "N/A",
      "unit": "hospitals",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 10,
      "comparability_note_zh": "公司披露为超过 3,000 家，此处 canonical value 记录披露下限。",
      "comparability_note_en": "The company disclosed more than 3,000 hospitals; the canonical value records the disclosed floor."
    },
    {
      "metric_id": "tertiary_hospitals_floor",
      "label": "三级医院覆盖",
      "label_en": "Tertiary hospitals reached",
      "period": "2026-06-30",
      "value": 1000,
      "currency": "N/A",
      "unit": "hospitals",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 10,
      "comparability_note_zh": "公司披露为超过 1,000 家，此处 canonical value 记录披露下限。",
      "comparability_note_en": "The company disclosed more than 1,000 tertiary hospitals; the canonical value records the disclosed floor."
    },
    {
      "metric_id": "approved_products",
      "label": "已获批产品",
      "label_en": "Approved products",
      "period": "2026-06-30",
      "value": 63,
      "currency": "N/A",
      "unit": "products",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 13
    },
    {
      "metric_id": "registered_patents",
      "label": "注册专利",
      "label_en": "Registered patents",
      "period": "2026-06-30",
      "value": 190,
      "currency": "N/A",
      "unit": "patents",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 14
    },
    {
      "metric_id": "rd_staff",
      "label": "研发人员",
      "label_en": "R&D staff",
      "period": "2026-06-30",
      "value": 89,
      "currency": "N/A",
      "unit": "people",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 13
    },
    {
      "metric_id": "international_regulatory_approvals_floor",
      "label": "海外监管批准及注册",
      "label_en": "International regulatory approvals and registrations",
      "period": "2026-06-30",
      "value": 200,
      "currency": "N/A",
      "unit": "approvals",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 10,
      "comparability_note_zh": "公司披露为超过 200 项，此处 canonical value 记录披露下限。",
      "comparability_note_en": "The company disclosed more than 200 approvals and registrations; the canonical value records the disclosed floor."
    }
  ],
  "cash_flow": [
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2023",
      "value": 79.856,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 20
    },
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2024",
      "value": 94.515,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 20
    },
    {
      "metric_id": "net_operating_cash",
      "label": "经营活动现金流净额",
      "label_en": "Net cash from operating activities",
      "period": "FY2025",
      "value": 157.116,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 20
    },
    {
      "metric_id": "cash_and_cash_equivalents",
      "label": "现金及现金等价物",
      "label_en": "Cash and cash equivalents",
      "period": "2026-06-30",
      "value": 819.64,
      "currency": "RMB",
      "unit": "million",
      "value_type": "company_disclosure",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pdf_page": 18
    }
  ],
  "management": [
    {
      "name_zh": "董文兴",
      "name_en": "Wenxing Dong",
      "role_zh": "创办人、董事长、执行董事、首席执行官兼总经理",
      "role_en": "Founder, Chairman, Executive Director, Chief Executive Officer and General Manager",
      "bio_zh": "负责集团整体战略、业务方向及研发决策，拥有医疗器械行业创业与管理经验。",
      "bio_en": "Responsible for the Group's overall strategy, business direction and R&D decisions, with entrepreneurship and management experience in the medical-device industry.",
      "period": "Prospectus dated 24 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 177,
      "portrait_status": "not_published_in_reviewed_official_sources"
    },
    {
      "name_zh": "和路",
      "name_en": "Lu He",
      "role_zh": "执行董事、财务总监、董事会秘书兼副总经理",
      "role_en": "Executive Director, Finance Director, Board Secretary and Deputy General Manager",
      "bio_zh": "负责监督公司财务、资本市场及公司治理事务；加入集团前拥有会计师事务所审计及投资银行相关经验。",
      "bio_en": "Oversees finance, capital-markets and corporate-governance matters; before joining the Group, he gained experience in audit and investment banking.",
      "period": "Prospectus dated 24 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 177,
      "portrait_status": "not_published_in_reviewed_official_sources"
    },
    {
      "name_zh": "刘少斌",
      "name_en": "Shaobin Liu",
      "role_zh": "首席运营官兼副总经理",
      "role_en": "Chief Operating Officer and Deputy General Manager",
      "bio_zh": "负责集团运营管理，拥有制造与运营管理经验；加入集团前曾在医疗器械及工业企业任职。",
      "bio_en": "Responsible for the Group's operations, with manufacturing and operational-management experience gained across medical-device and industrial companies.",
      "period": "Prospectus dated 24 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 182,
      "portrait_status": "not_published_in_reviewed_official_sources"
    }
  ],
  "risks": [
    {
      "title": "产品研发与注册转化",
      "title_en": "Product development and regulatory conversion",
      "text": "研发团队变化、资金、验证或临床试验结果可能影响新产品开发进度、性能及后续注册与商业化。",
      "text_en": "Changes in R&D personnel, funding, validation or clinical-trial outcomes may affect new-product timelines, performance, registration and commercialisation.",
      "period": "Prospectus dated 24 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 40
    },
    {
      "title": "产品质量、生产与召回",
      "title_en": "Product quality, manufacturing and recalls",
      "text": "产品不良事件、生产中断或缺陷可能引致监管审查、产品召回、责任索赔及声誉损害。",
      "text_en": "Adverse product events, manufacturing disruption or defects may lead to regulatory scrutiny, recalls, liability claims and reputational harm.",
      "period": "Prospectus dated 24 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 42
    },
    {
      "title": "集采与价格压力",
      "title_en": "Volume-based procurement and pricing pressure",
      "text": "集中采购、医院及经销商价格压力可能限制成本上涨向终端转嫁，并对售价和利润率造成影响。",
      "text_en": "Volume-based procurement and pricing pressure from hospitals and distributors may limit cost pass-through and affect selling prices and margins.",
      "period": "Prospectus dated 24 April 2026",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 43
    },
    {
      "title": "客户集中度",
      "title_en": "Customer concentration",
      "text": "2025 年五大客户贡献收入的 57.7%，最大客户贡献 20.8%；主要客户采购变化可能影响收入表现。",
      "text_en": "The five largest customers contributed 57.7% of FY2025 revenue and the largest customer 20.8%; changes in major-customer purchasing may affect revenue.",
      "period": "FY2025",
      "value_type": "company_disclosure_summary",
      "source_type": "hkex_filing",
      "source_url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pdf_page": 16
    }
  ],
  "reports": [
    {
      "year": 2025,
      "published": "2026-04-24",
      "title": "Prospectus with audited FY2023–FY2025 track record",
      "title_zh": "招股章程（含 2023–2025 经审核往绩）",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0424/2026042400054_c.pdf",
      "pages": 370
    }
  ],
  "announcements": [
    {
      "id": "2026-share-repurchase-plan",
      "published": "2026-08-18",
      "title": "Voluntary announcement — share repurchase plan",
      "title_zh": "自愿性公告——股份回购计划",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0818/2026081800942.pdf",
      "pages": 2
    },
    {
      "id": "2026-interim-results",
      "published": "2026-08-17",
      "title": "Interim results for the six months ended 30 June 2026",
      "title_zh": "截至 2026 年 6 月 30 日止六个月中期业绩",
      "url": "https://www1.hkexnews.hk/listedco/listconews/sehk/2026/0817/2026081701174_c.pdf",
      "pages": 25
    }
  ],
  "publication_relationship": {
    "type": "unpaid_pilot",
    "labelZh": "免费试点页面",
    "labelEn": "Unpaid pilot profile",
    "disclosureZh": "本页为 PureIR 免费试点页面，由 PureIR 根据正式披露独立整理；公司未付费委托，也未参与评级或投资判断。",
    "disclosureEn": "This is an unpaid PureIR pilot independently prepared from formal disclosure. The company did not commission or pay for the profile and did not participate in any rating or investment judgement."
  }
}